A new study suggests that a blood test measuring p-tau217 could help identify people at higher risk of developing cognitive impairment years before symptoms appear. Researchers reported that the biomarker showed strong long-term predictive value, adding to growing interest in blood-based tools for Alzheimer’s-related screening.
According to the findings, asymptomatic individuals with very high p-tau217 levels at baseline faced a 38% risk of cognitive impairment within five years. That result points to the test’s potential as an early warning marker, especially in people who do not yet show clear memory or thinking problems.
The research highlights the prognostic power of p-tau217 as a simple blood-based biomarker, which could be easier to use than more invasive or expensive methods. If validated further, it may help clinicians better assess future Alzheimer’s risk and monitor people who may benefit from closer follow-up.
While the findings do not mean the test is a standalone diagnosis, they strengthen the case for blood testing as part of earlier detection strategies for neurodegenerative disease. The study adds evidence that p-tau217 may play an important role in forecasting cognitive decline over a multi-year period.
